Yearly influenza vaccinations: a double-edged sword? (Q57109445)

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Cost-effectiveness of influenza vaccination of healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

1 reference

7 January 2021

Human infection with influenza H9N2.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Probable person-to-person transmission of avian influenza A (H5N1)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Update on avian influenza A (H5N1) virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterosubtypic immunity to influenza A virus: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Cytotoxic T-cell immunity to influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Cellular immunity and memory to respiratory virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Influenza: Accounting for Prior Immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Avian Influenza A (H5N1) Age Distribution in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Influenza and the rates of hospitalization for respiratory disease among infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Seroprevalence of influenza A and B in German infants and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Correlates of protection: novel generations of influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Use of viral vectors for the development of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970263-4

7 January 2021